24周对12周的Decapeptyl SR治疗在中部早期青春期的有效性:英国多中心回顾性队列研究
Rachel Varughese1,2, Lydia Lake1, Bharathy Kothayan1
1Centre for Endocrinology, William Harvey Research Institute, QMUL, London, UK.
The Journal of clinical endocrinology and metabolism
|March 7, 2026
概括
24周一次的Decapeptyl SR (Triptorelin) 治疗与中部早发性青春期 (CPP) 的儿童每12周一次的治疗方案一样有效. 这种较长的间隔提供了可比的结果,改善了患者的偏好和潜在的更好的坚持.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 生殖医学 生殖医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 中部早发性青春期 (CPP) 涉及青春期的早期发作,原因是下丘脑-垂体-腺 (HPG) 轴的过早激活.
- 激素释放激素类似物 (GnRHa) 是抑制HPG轴活性和减缓青春期进展的标准治疗方法.
- Decapeptyl SR (Triptorelin) 是一种GnRHa,可用于不同的剂量频率.
研究的目的:
- 为了比较24周的Decapeptyl SR与12周的Decapeptyl SR在治疗儿童中CPP的疗效和耐受性.
- 评估不同剂量频率对HPG轴抑制和青春期进展的影响.
- 为了评估患者的偏好和较少频繁的剂量计划的潜在益处.
主要方法:
- 一个多中心的回顾性队列研究,涉及英国的儿科内分泌中心.
- 患有CPP的患者每12周接受11.25毫克的Decapeptyl SR或每24周接受22.5毫克的Decapeptyl SR.
- 收集了临床,生化和放射学数据,以评估HPG轴抑制和青春期进展.
主要成果:
- 分析了164名患者 (69名12周一次,95名24周一次).
- 这两种疗法都实现了有效的HPG轴抑制,具有可比的白化激素,卵泡刺激激素和性类固醇水平.
- 临床结果 (身高速度,BMI,坦纳阶段) 和青春期进展在各组之间是相似的.
- 24周的治疗方案被很好地容忍,所有表达偏好的患者都喜欢这个时间表.
结论:
- 24周一次的Decapeptyl SR疗法对CPP管理有效且耐受良好,证明其与12周一次的疗法具有临床等价性.
- 减少注射频率可能会提高治疗坚持和患者满意度.
- 本研究提供了第一个支持CPP24周时间表的比较分析,有可能节省成本并简化监控.
相关概念视频
01:18Transdermal Drug Delivery Systems
80
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
80
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
564
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
564
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
519
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519